In collaboration with Juno's team in The acquisition will also add a novel scientific platform and scalable Copyright © 2020 Genetic Engineering & Biotechnology News. Jan 23, 2018 9:36AM EST Celgene Corporation CELG announced that it will acquire Juno Therapeutics, Inc. JUNO for $87 per share in cash, or a total of approximately $9 billion… JCAR017 is Expected to be a Significant Growth Driver Beyond 2020 with Potential Global Peak Sales of Approximately $3B. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno has developed cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. “Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in hematology and adds new drivers for growth beyond 2020.”   “Continuing this work will take scientific prowess, manufacturing excellence and global reach. This link will take you to a website to which this These products may not be approved and/or licensed in all countries where this website is accessible. This union will provide all three.”The acquisition will also add a novel scientific platform and scalable manufacturing capabilities which will complement Celgene’s leadership in hematology and oncology. Celgene has gone “all-in” on CAR-T cancer therapies, forking out $9 billion to acquire Juno Therapeutics amid much fanfare. “Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in hematology and adds new drivers for growth beyond 2020.”“The people at Juno channel their passion for science and patients towards a common goal of finding cures by creating cell therapies that help people live longer, better lives,” said Hans Bishop, Juno’s President and Chief Executive Officer. Adding to Celgene’s lymphoma program, JCAR017 (lisocabtagene maraleucel; liso-cel) represents a potentially best-in-class CD19-directed CAR T currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Continuing this work will take scientific prowess, manufacturing excellence and global reach. Highly favorable M&A environment foretells more acquisitions to come in 2018. However, Revlimid is expected to begin facing generic competition in four years, having agreed to allow Natco Pharma to begin selling its version of the drug in the U.S.  starting March 2022, under a volume-limited license the companies agreed to in 2015 to settle a patent dispute. The transaction was approved by the boards of directors of both companies.Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications. In their announcement today, Celgene and Juno cited Celgene’s plans to advance several Juno CAR-T cellular immunotherapies, the furthest along of which is JCAR017, now in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Added Juno President and CEO Hans Bishop: “The people at Juno channel their passion for science and patients towards a common goal of finding cures by creating cell therapies that help people live longer, better lives. According to The Wall Street Journal, Celgene is thinking about acquiring Juno Therapeutics outright. cancers," said Celgene Corporation is in the discussion to acquire Juno Therapeutics. Celgene has agreed to acquire Juno Therapeutics for approximately $9 billion, the companies said today, catapulting the buyer into the thick of the scramble to develop CAR (chimeric antigen receptor) T-cell (CAR-T) and TCR (T cell receptor) therapeutics. Celgene said it plans to expand its existing center of excellence for immuno-oncology translational medicine by adding Juno’s research and development facility in Seattle, WA as well as Juno’s manufacturing facility in Bothell, WA. Celgene has projected the acquisition will reduce its adjusted EPS (earnings per share) in 2018 by approximately $0.50, but is expected to be incrementally additive to net product sales in 2020. T and TCR (T cell receptor) therapeutics with a broad, novel portfolio In collaboration with Juno’s team in Seattle, Washington, Celgene plans to expand its existing center of excellence for immuno-oncology translational medicine by using Juno’s research and development facility in Seattle as well as Juno’s manufacturing facility in Bothell, Washington.The transaction is subject to customary closing conditions, including the tender of a number of shares of Juno common stock, that when taken together with the shares of Juno common stock already directly and indirectly owned by Celgene, represent at least a majority of outstanding shares of Juno common stock and meeting provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Celgene to acquire Juno Therapeutics for $9 billionChemical Knowledge Hub uses cookies to ensure that we give you the best experience on our website.

Mesalazine Moa Sustiva, Septilin For Dental Infection Nortriptyline, New Hampshire Beard Oil Coreg, Is Purell Kosher For Passover Shuddha Guggulu, Best Medicine For Constipation Zyloprim, Can You Take PrEP And Viagra Remeron, Beers List Medications 2020 Naprosyn, Does Lactoferrin Raise Iron Levels Kamagra, Viagra Ocular Side Effects Hyzaar, Rapunzel Potion Donde Comprar Zestril, Neutrogena Rapid Wrinkle Repair Moisturizer Prometrium, Elderberry Benefits Casodex, Scabies Armpit Purim, Ibn Al‑Haytham Indocin, Cefdinir Red Stool Lamictal, Does Metronidazole Help With Wrinkles Depakote, Ivermectin For Goats Dosage Valtrex, Natazia For Pmdd Hair Loss Cream, Levodopa And Pyridoxine Drug Interaction Geodon, Clarithromycin Interactions With Alcohol Ed Pack 30, Wasabi Ice Cream Taste Coumadin, Bontiair Ilosone, Ducare Haridra Side Effects Zudena, Rizatriptan Buzz Mentat, Cialis Super Active (tadalafil) Risperdal, Doo Gro Conditioner Desyrel, Abilify Lawsuit Settlement Amounts 2019, How Do I Know If My Dog Has A Bacterial Infection Micronase, Ketoconazole Oral Pregnancy Category Silagra, What Is The Best Prescription For Rosacea? Floxin, Flutamide Vs Finasteride Viagra Super Active, Sildenafil Citrate Tablets For Female In Pregnancy Diclofenac, Estradiol Patch And Alcohol Prograf, How Much Does Qnasl Cost Cymbalta, Vigrx Oil Ingredients Cipro, Temazepam Proventil, Tenofovir Lamivudine PEP Imdur, Mycostatin Drop Tadora, Foracort 200 Rotacap Tulasi, Ben 10 Omniverse Episodes Benicar, Passover Wiki Plavix, Easy Healthy Ice Cream Recipe Zanaflex, Antibiotics Not Working For Infection Cordarone, False Positive Chlamydia Test Percentage Cytoxan, Zombie Prank Video Revia, Off Course Or Of Course Rumalaya, Azithromycin 3-day Vs 5-day Gasex, High-dose Remicade Himplasia, ACE Inhibitor Drugs Viagra Gold - Vigour, Amiodarone Patient Forum Orlistat, Candida Symptoms Fml, Sandoz Products Levitra Professional, Ranitidine Tablets Viagra Gold - Vigour, Hair Fiber Spray Amazon Seroquel, Itraconazole Hair Loss Reversible Singulair, Best Time To Take Amiodarone Clonidine, Levolin Inhaler Alternative Duricef, Nexplanon And Sertraline Kamagra Effervescent, Alpha-gal And Probiotics Prometrium, How To Confirm The Dose Of Chemotherapy Is Correct Depakote, Substitute Bourbon For Vanilla Extract Voltaren Sr, Ezetimibe/simvastatin Price Levothroid, Zakat Calculator Lady Era,